1492 Capital Management LLC Takes Position in Denali Therapeutics Inc. $DNLI

1492 Capital Management LLC bought a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 67,487 shares of the company’s stock, valued at approximately $1,114,000.

Other large investors have also modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Denali Therapeutics by 4.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,507 shares of the company’s stock valued at $1,210,000 after purchasing an additional 3,432 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Denali Therapeutics by 58.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company’s stock valued at $22,732,000 after purchasing an additional 614,555 shares in the last quarter. Empowered Funds LLC grew its stake in Denali Therapeutics by 11.0% during the 1st quarter. Empowered Funds LLC now owns 20,639 shares of the company’s stock valued at $281,000 after purchasing an additional 2,052 shares in the last quarter. Woodline Partners LP grew its stake in Denali Therapeutics by 13.5% during the 1st quarter. Woodline Partners LP now owns 113,517 shares of the company’s stock valued at $1,543,000 after purchasing an additional 13,517 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Denali Therapeutics by 1.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 191,613 shares of the company’s stock valued at $2,681,000 after purchasing an additional 3,210 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on DNLI. Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Monday, April 20th. Wall Street Zen raised shares of Denali Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. BTIG Research reissued a “buy” rating and issued a $39.00 target price on shares of Denali Therapeutics in a research report on Monday, May 11th. Wedbush dropped their target price on shares of Denali Therapeutics from $25.00 to $23.00 and set an “outperform” rating for the company in a research report on Friday, May 8th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $40.00 target price on shares of Denali Therapeutics in a report on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Denali Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $34.25.

Denali Therapeutics Trading Up 1.6%

NASDAQ:DNLI opened at $19.66 on Thursday. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $19.70 and its two-hundred day moving average is $19.31. Denali Therapeutics Inc. has a 52 week low of $12.58 and a 52 week high of $23.77. The company has a market cap of $3.12 billion, a PE ratio of -6.83 and a beta of 1.03.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Thursday, May 7th. The company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04. During the same period in the prior year, the company posted ($0.78) EPS. On average, analysts predict that Denali Therapeutics Inc. will post -2.74 EPS for the current year.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.